Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC-Reference-Cited by-同舟云学术

Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC

Published:2021-08-25 Issue:5 Volume:74 Page:2544-2560
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Yi Chenhe¹²^ORCID,Chen Lirong³^ORCID,Lin Zhifei¹²^ORCID,Liu Lu⁴,Shao Weiqing¹²,Zhang Rui¹²,Lin Jing¹²,Zhang Jubo⁴,Zhu Wenwei¹²,Jia Huliang¹²,Qin Lunxiu¹²^ORCID,Lu Lu¹²,Chen Jinhong¹²^ORCID

Affiliation:

1. Department of General Surgery Huashan HospitalFudan University Shanghai PR China

2. Cancer Metastasis InstituteFudan University Shanghai PR China

3. Department of Digestive Diseases Huashan HospitalFudan University Shanghai PR China

4. Department of Infectious Diseases Huashan HospitalFudan University Shanghai PR China

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31921

Reference41 articles.

1. Hepatocellular Carcinoma

2. Hepatocellular carcinoma

3. Immune oncology in hepatocellular carcinoma—hype and hope

4. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

5. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study;Neoplasia;2024-11

2. New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. Second-line systemic therapy after atezolizumab plus bevacizumab: Is it time to boldly go beyond the known?;Digestive and Liver Disease;2024-09

4. Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis;Frontiers in Immunology;2024-08-30

5. The potential of lenvatinib in breast cancer therapy;Medical Oncology;2024-08-22